<DOC>
	<DOCNO>NCT01646827</DOCNO>
	<brief_summary>The purpose study determine whether aripiprazole injection shoulder buttock produce similar effect body</brief_summary>
	<brief_title>An Open Label Study Aripiprazole Intramuscular Injection Subjects With Schizophrenia</brief_title>
	<detailed_description>Extended-release gluteal intramuscular ( IM ) injection aripiprazole test subject schizophrenia safety tolerability . This study compare gluteal IM aripiprazole injection deltoid IM aripiprazole injection safety tolerability .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Diagnosis schizophrenia Stabilized oral antipsychotic medication Good physical health BMI 18 35 kg/m2 Prior history tolerate aripiprazole Sexually active male commit utilizing 2 approve birth control method remain abstinent trial 180 day follow last dose trial medication , orchidectomy sexually active female childbearing potential commit utilize 2 approved birth control method remain abstinent trial 150 day follow last dose trial medication . Abstinence permit confirm documented every trial visit . If employing birth control , 2 follow precaution must use : vasectomy , tubal ligation , vaginal diaphragm , intrauterine device , birth control pill , birth control depot injection , implant , condom sponge spermicide . Subjects meet DSMIVTR criterion substance abuse dependence within past 180 day ; include alcohol benzodiazepine , exclude caffeine nicotine . Subjects positive drug screen cocaine drug abuse ( exclude stimulant prescribe medication marijuana ) . Use psychotropic medication current antipsychotic medication . Use CYP2D6 CYP3A4 inhibitor , CYP3A4 inducer within 14 day ( fluoxetine 28 day ) prior dose duration trial . Females pregnant lactating . Subjects participate previous IM depot trial within last one year ; previously enrol received trial medication aripiprazole IM depot clinical trial . Any major surgery within 30 day prior enrollment . Evidence organ dysfunction clinically significant deviation normal physical , electrocardiographic , clinical laboratory examination . Subjects significant risk commit suicide base history , routine psychiatric status examination , investigator 's judgment , answer `` yes '' question 4 5 ( current last 30 day ) Baseline/Screening version Columbia Suicide Severity Rating Scale ( CSSRS ) . Subjects currently acute relapse schizophrenia . Subjects current DSMIVTR diagnosis schizophrenia , include schizoaffective disorder , major depressive disorder , bipolar disorder , delirium , dementia , amnestic cognitive disorder . Also , subject borderline , paranoid , histrionic , schizotypal , schizoid antisocial personality disorder . Subjects consider treatmentresistant antipsychotic medication . Subjects electroconvulsive therapy within 2 month administration trial drug . Subjects history neuroleptic malignant syndrome clinically significant tardive dyskinesia assess investigator . Any sound medical reason enter trial , determine clinical investigator . Subjects know allergic , intolerant , unresponsive prior treatment aripiprazole quinolinones .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Schizophrenia , extend release antipsychotic</keyword>
</DOC>